Beneficial effects of K-ATP channel openers in diabetes: An update on mechanisms and clinical experiences

Diabetes, Obesity and Metabolism

Volumn 11, Issue SUPPL. 4, 2009, Pages 143-148

  Grill, V ^a,b   Radtke, M ^a,b   Qvigstad, E ^a,b   Kollind, M ^a,c   Bjorklund A ^d  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c Levanger Hospital   (Norway)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Diabetes; Diazoxide; Hypoxia; Islets of Langerhans

Indexed keywords

DIAZOXIDE; GLUCOSE; INSULIN; PLACEBO;

ARTICLE; BEDTIME DOSAGE; CELL HYPOXIA; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MECHANISM; DRUG RESPONSE; EDEMA; GLYCEMIC CONTROL; HUMAN; HYPERINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIAZOXIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; KATP CHANNELS;

EID: 70350331457     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01119.x     Document Type: Article

References (34)

1. Overview of 6 years therapy of type 2 diabetes: a progressive disease. Diabetes 1995, 44:1249-1258. UK Prospective Diabetes Study Group
2. Ilkova H, Glaser B, Tunçkale A. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997, 20:1353-1356.
3. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998, 128:517-523. The Diabetes Control and Complications Trial Research Group
4. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 2008, 29:351-366.
5. Tajiri Y, Möller C, Grill V. Long term effects of aminoguanidine on insulin release and biosynthesis. Evidence that the formation of advanced glycosylation end products inhibits B-cell function. Endocrinology 1997, 138:273-280.
6. Sako Y, Grill V. A 48 h lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B-cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 1990, 127:1580-1589.
7. Sako Y, Grill V. Coupling of B-cell desensitization by hyperglycemia to excessive stimulation and circulating insulin in glucose-infused rats. Diabetes 1990, 39:1580-1583.
8. Ma Z, Portwood N, Brodin D. Effects of diazoxide on gene expression in rat pancreatic islets are largely linked to elevated glucose and potentially serve to enhance beta cell sensitivity. Diabetes 2007, 56:1095-1106.
9. Riess ML, Camara AK, Heinen A. KATP channel openers have opposite effects on mitochondrial respiration under different energetic conditions. J Cardiovasc Pharmacol 2008, 51:483-491.
10. Larssson-Nyre'n G, Ma Z, Grill V. Effects of diazoxide on beta cell mitochondrial function and mass are glucose-dependent. Diabetologia 2008, 51(Suppl. 1):S205. (abstract)
11. Schäfer G, Wegener C, Portenhauser R. Diazoxide, an inhibitor of succinate oxidation. Biochem Pharmacol 1969, 18:2678-2681.
12. Dionne KE, Colton CK, Yarmush ML. Effect of hypoxia on insulin secretion by isolated rat and canine islets of Langerhans. Diabetes 1993, 42:12-21.
13. Gribble FM. Intolerant of glucose and gasping for oxygen. Nat Med 2009, 15:247-249.
14. Stokes R, Cheng K, Scott C. Increased expression of hypoxia inducible factor 1a (HIF1a) markedly improves outcomes following transplantation of human islets into mice. Diabetes 2007, 56(Suppl. 1):A47. (abstract)
15. Hanley PJ, Daut J. K(ATP) channels and preconditioning: a re-examination of the role of mitochondrial K(ATP) channels and an overview of alternative mechanisms. J Mol Cell Cardiol 2005, 39:17-50.
16. Björklund A, Ma Z, Brismar K. Diazoxide protects against hypoxia-induced beta cell damage. Diabetologia 2008, 51(Suppl. 1):S225. (abstract)
17. Sandler S, Andersson AK, Larsson J. Possible role of an ischemic preconditioning-like response mechanism in K(ATP) channel opener-mediated protection against streptozotocin-induced suppression of rat pancreatic islet function. Biochem Pharmacol 2008, 76:1748-1756.
18. Greenwood RH, Mahler RF, Hales CN. Improvement in insulin secretion in diabetes after diazoxide. Lancet 1976, 307:444-447.
19. Qvigstad E, Kollind M, Grill V. Nine weeks of bedtime diazoxide is well tolerated and beta-cell beneficial in subjects with type 2 diabetes. Diabet Med 2004, 21:73-76.
20. Olczak SA, Greenwood RH, Hales CN. Post-receptor insulin resistance after diazoxide in non-insulin dependent diabetes. Horm Metab Res 1986, 18:38-41.
21. Alemzadeh R, Slonim AE, Zdanowicz MM. Modification of insulin resistance by diazoxide in obese Zucker rats. Endocrinology 1993, 133:705-712.
22. Radtke M, Kollind M, Qvigstad E. Twelve weeks of diazoxide treatment without insulin supplementation in type 2 diabetes is feasible but does not improve insulin secretion. Diabet Med 2007, 24:172-177.
23. Rasmussen SB, Sørensen TS, Hansen JB. Functional rest through intensive treatment with insulin and potassium channel openers preserves residual beta-cell function and mass in acutely diabetic BB rats. Horm Metab Res 2000, 32:294-300.
24. Skak K, Gotfredsen CF, Lundsgaard D. Improved beta-cell survival and reduced insulitis in a type 1 diabetic rat model after treatment with a beta-cell-selective K(ATP) channel opener. Diabetes 2004, 53:1089-1095.
25. Björk E, Berne C, Kämpe O. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 1996, 45:1427-1430.
26. Ortqvist E, Björk E, Wallensteen M. Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes. Diabetes Care 2004, 27:2191-2217.
27. Taylor AE. Insulin-lowering medications in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2000, 27:583-595.
28. Alemzadeh R, Langley G, Upchurch L. Beneficial effect of diazoxide in obese hyperinsulinemic adults. J Clin Endocrinol Metab 1998, 83:1911-1915.
29. Due A, Flint A, Eriksen G. No effect of inhibition of insulin secretion by diazoxide on weight loss in hyperinsulinaemic obese subjects during an 8-week weight-loss diet. Diabetes Obes Metab 2007, 9:566-574.
30. Guldstrand M, Grill V, Björklund A. Improved beta cell function after short-tem treatment with diazoxide in obese subjects with type2 diabetes. Diabetes Metabolism 2002, 28:448-456.
31. Remedi MS, Nichols CG. Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells. PLoS Med 2008, 5:e206.
32. Alvarsson M, Sundkvist G, Lager I. Effects of insulin vs. glibenclamide in recently diagnosed type 2 diabetic patients: a 4-year follow-up. Diabetes Obes Metab 2008, 10:421-429.
33. Hansen JB. Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives. Curr Med Chem 2006, 13:361-376.
34. Clausson P, Alvarsson M, Grill V. Enhancement of β-cell secretion by blood glucose normalization relates to fasting C-peptide levels. J Intern Med 1997, 241:493-500.